sub:assertion {
  d:DB05456 v:identifier "DB05456" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05456" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05456> ;
    dv:drugbank-id "DB05456" ;
    dv:x-cas <http://bio2rdf.org/cas:> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:4952476> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:6449792> ;
    dct:description "ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells including those in the arterial wall. LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway. It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis. Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes."@en ;
    dct:identifier "drugbank:DB05456" ;
    dct:title "ETC-588"@en ;
    a dv:Drug ;
    rdfs:label "ETC-588 [drugbank:DB05456]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05456> .
}